Clearside Biomedical Inc. (NASDAQ:CLSD) went up by 9.72% from its latest closing price compared to the recent 1-year high of $4.13. The company’s stock price has collected 14.49% of gains in the last five trading sessions. Press Release reported on 01/12/21 that Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Is It Worth Investing in Clearside Biomedical Inc. (NASDAQ :CLSD) Right Now?
Plus, the 36-month beta value for CLSD is at 1.45. Opinions of the stock are interesting as 3 analysts out of 6 who provided ratings for Clearside Biomedical Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $6.13, which is $1.85 above the current price. CLSD currently public float of 44.34M and currently shorts hold a 2.25% ratio of that float. Today, the average trading volume of CLSD was 598.46K shares.
CLSD’s Market Performance
CLSD stocks went up by 14.49% for the week, with a monthly jump of 103.61% and a quarterly performance of 165.10%, while its annual performance rate touched 64.58%. The volatility ratio for the week stands at 13.12% while the volatility levels for the past 30 days are set at 12.56% for Clearside Biomedical Inc.. The simple moving average for the period of the last 20 days is 49.44% for CLSD stocks with a simple moving average of 111.82% for the last 200 days.
Analysts’ Opinion of CLSD
Many brokerage firms have already submitted their reports for CLSD stocks, with ROTH Capital repeating the rating for CLSD by listing it as a “Buy.” The predicted price for CLSD in the upcoming period, according to ROTH Capital is $8 based on the research report published on May 13th of the previous year 2020.
CLSD Trading at 88.57% from the 50-Day Moving Average
After a stumble in the market that brought CLSD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.36% of loss for the given period.
Volatility was left at 12.56%, however, over the last 30 days, the volatility rate increased by 13.12%, as shares surge +89.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +192.59% upper at present.
During the last 5 trading sessions, CLSD rose by +14.49%, which changed the moving average for the period of 200-days by +124.43% in comparison to the 20-day moving average, which settled at $2.74. In addition, Clearside Biomedical Inc. saw 44.16% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CLSD starting from WHITMORE BRADFORD T, who purchase 350,750 shares at the price of $2.85 back on Jan 06. After this action, WHITMORE BRADFORD T now owns 3,529,845 shares of Clearside Biomedical Inc., valued at $999,988 using the latest closing price.
WHITMORE BRADFORD T, the 10% Owner of Clearside Biomedical Inc., purchase 51,195 shares at $1.95 during a trade that took place back on Dec 24, which means that WHITMORE BRADFORD T is holding 3,179,095 shares at $99,897 based on the most recent closing price.
Stock Fundamentals for CLSD
Current profitability levels for the company are sitting at:
- -1394.57 for the present operating margin
The net margin for Clearside Biomedical Inc. stands at -1416.01. The total capital return value is set at -118.47, while invested capital returns managed to touch -125.82. Equity return is now at value -153.40, with -65.30 for asset returns.
Based on Clearside Biomedical Inc. (CLSD), the company’s capital structure generated 57.44 points at debt to equity in total, while total debt to capital is 36.49. Total debt to assets is 23.94, with long-term debt to equity ratio resting at 42.27. Finally, the long-term debt to capital ratio is 26.85.
When we switch over and look at the enterprise to sales, we see a ratio of 43.49, with the company’s debt to enterprise value settled at 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.31.